Loading patent…
AssigneesMillennium Pharmaceuticals, Inc., Amgen British Columbia
InventorsSamuel S. Nam, Edward A. Greenfield, Theresa L. O'Keefe, Shixin Qin, John Babcook
Estimating the term…
Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
An anti-GCC antibody molecule comprising a light chain variable region and a heavy chain variable region, wherein said light chain variable region comprises three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), and said heavy chain variable region comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), wherein the light chain variable region comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO:
An immunoconjugate of formula (I-4):
An immunoconjugate of formula (I-5):
An immunoconjugate of formula (I-7):
Dependencies are inferred from the claim text.